Ten-year results with the St. Jude medical prosthesis

Chandra K. Nair, Syed M. Mohiuddin, Daniel E. Hilleman, Richard Schultz, Robert T. Bailey, Cornelia T. Cook, Michael H. Sketch

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Although the hemodynamic characteristics and durability of the St. Jude valve prosthesis have been reported, the need for and the degree of anticoagulation in patients who receive these valves remain uncertain. Our 10-year experience with 165 patients (100 men and 65 women, mean age of 58 ± 13 years), who underwent valve replacement with St. Jude prostheses, is reported. Of the 165 patients, 147 were treated with warfarin. A prothrombin time 1.3 to 1.8 times control (range 15 to 20 seconds) was maintained in 134 patients with single valve and 1.8 to 2 times control (range 20 to 25 seconds) in 13 patients with double valve prostheses. The 10-year actuarial event-free incidence from thromboembolic and hemorrhagic complications was 84 and 95%, respectively. Of the 8 patients receiving antiplatelet therapy alone, 4 had thromboembolic events. Of the 10 patients on neither warfarin nor antiplatelet therapy, 3 had thromboembolic events. The 10-year actuarial event-free incidence from valve failure was 95%. The 10-year actuarial patient survival was 55%. Thus, the St. Jude valve is a safe and reliable prosthesis with acceptable overall long-term performance in patients given a modest anticoagulation regimen. Patients who receive St. Jude prosthetic valves without anticoagulants have a high incidence of thromboembolic events despite therapy with antiplatelet agents.

Original languageEnglish
Pages (from-to)217-225
Number of pages9
JournalAmerican Journal of Cardiology
Volume65
Issue number3
DOIs
StatePublished - Jan 15 1990

Fingerprint

Prostheses and Implants
Warfarin
Incidence
Platelet Aggregation Inhibitors
Prothrombin Time
Anticoagulants
Therapeutics
Hemodynamics
Survival

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ten-year results with the St. Jude medical prosthesis. / Nair, Chandra K.; Mohiuddin, Syed M.; Hilleman, Daniel E.; Schultz, Richard; Bailey, Robert T.; Cook, Cornelia T.; Sketch, Michael H.

In: American Journal of Cardiology, Vol. 65, No. 3, 15.01.1990, p. 217-225.

Research output: Contribution to journalArticle

Nair, Chandra K. ; Mohiuddin, Syed M. ; Hilleman, Daniel E. ; Schultz, Richard ; Bailey, Robert T. ; Cook, Cornelia T. ; Sketch, Michael H. / Ten-year results with the St. Jude medical prosthesis. In: American Journal of Cardiology. 1990 ; Vol. 65, No. 3. pp. 217-225.
@article{66134e0d0f904913971f507d4e9de441,
title = "Ten-year results with the St. Jude medical prosthesis",
abstract = "Although the hemodynamic characteristics and durability of the St. Jude valve prosthesis have been reported, the need for and the degree of anticoagulation in patients who receive these valves remain uncertain. Our 10-year experience with 165 patients (100 men and 65 women, mean age of 58 ± 13 years), who underwent valve replacement with St. Jude prostheses, is reported. Of the 165 patients, 147 were treated with warfarin. A prothrombin time 1.3 to 1.8 times control (range 15 to 20 seconds) was maintained in 134 patients with single valve and 1.8 to 2 times control (range 20 to 25 seconds) in 13 patients with double valve prostheses. The 10-year actuarial event-free incidence from thromboembolic and hemorrhagic complications was 84 and 95{\%}, respectively. Of the 8 patients receiving antiplatelet therapy alone, 4 had thromboembolic events. Of the 10 patients on neither warfarin nor antiplatelet therapy, 3 had thromboembolic events. The 10-year actuarial event-free incidence from valve failure was 95{\%}. The 10-year actuarial patient survival was 55{\%}. Thus, the St. Jude valve is a safe and reliable prosthesis with acceptable overall long-term performance in patients given a modest anticoagulation regimen. Patients who receive St. Jude prosthetic valves without anticoagulants have a high incidence of thromboembolic events despite therapy with antiplatelet agents.",
author = "Nair, {Chandra K.} and Mohiuddin, {Syed M.} and Hilleman, {Daniel E.} and Richard Schultz and Bailey, {Robert T.} and Cook, {Cornelia T.} and Sketch, {Michael H.}",
year = "1990",
month = "1",
day = "15",
doi = "10.1016/0002-9149(90)90088-I",
language = "English",
volume = "65",
pages = "217--225",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Ten-year results with the St. Jude medical prosthesis

AU - Nair, Chandra K.

AU - Mohiuddin, Syed M.

AU - Hilleman, Daniel E.

AU - Schultz, Richard

AU - Bailey, Robert T.

AU - Cook, Cornelia T.

AU - Sketch, Michael H.

PY - 1990/1/15

Y1 - 1990/1/15

N2 - Although the hemodynamic characteristics and durability of the St. Jude valve prosthesis have been reported, the need for and the degree of anticoagulation in patients who receive these valves remain uncertain. Our 10-year experience with 165 patients (100 men and 65 women, mean age of 58 ± 13 years), who underwent valve replacement with St. Jude prostheses, is reported. Of the 165 patients, 147 were treated with warfarin. A prothrombin time 1.3 to 1.8 times control (range 15 to 20 seconds) was maintained in 134 patients with single valve and 1.8 to 2 times control (range 20 to 25 seconds) in 13 patients with double valve prostheses. The 10-year actuarial event-free incidence from thromboembolic and hemorrhagic complications was 84 and 95%, respectively. Of the 8 patients receiving antiplatelet therapy alone, 4 had thromboembolic events. Of the 10 patients on neither warfarin nor antiplatelet therapy, 3 had thromboembolic events. The 10-year actuarial event-free incidence from valve failure was 95%. The 10-year actuarial patient survival was 55%. Thus, the St. Jude valve is a safe and reliable prosthesis with acceptable overall long-term performance in patients given a modest anticoagulation regimen. Patients who receive St. Jude prosthetic valves without anticoagulants have a high incidence of thromboembolic events despite therapy with antiplatelet agents.

AB - Although the hemodynamic characteristics and durability of the St. Jude valve prosthesis have been reported, the need for and the degree of anticoagulation in patients who receive these valves remain uncertain. Our 10-year experience with 165 patients (100 men and 65 women, mean age of 58 ± 13 years), who underwent valve replacement with St. Jude prostheses, is reported. Of the 165 patients, 147 were treated with warfarin. A prothrombin time 1.3 to 1.8 times control (range 15 to 20 seconds) was maintained in 134 patients with single valve and 1.8 to 2 times control (range 20 to 25 seconds) in 13 patients with double valve prostheses. The 10-year actuarial event-free incidence from thromboembolic and hemorrhagic complications was 84 and 95%, respectively. Of the 8 patients receiving antiplatelet therapy alone, 4 had thromboembolic events. Of the 10 patients on neither warfarin nor antiplatelet therapy, 3 had thromboembolic events. The 10-year actuarial event-free incidence from valve failure was 95%. The 10-year actuarial patient survival was 55%. Thus, the St. Jude valve is a safe and reliable prosthesis with acceptable overall long-term performance in patients given a modest anticoagulation regimen. Patients who receive St. Jude prosthetic valves without anticoagulants have a high incidence of thromboembolic events despite therapy with antiplatelet agents.

UR - http://www.scopus.com/inward/record.url?scp=0025099766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025099766&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(90)90088-I

DO - 10.1016/0002-9149(90)90088-I

M3 - Article

C2 - 2296890

AN - SCOPUS:0025099766

VL - 65

SP - 217

EP - 225

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -